These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 32339503)
1. Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration. Takamori S; Matsubara T; Haratake N; Miura N; Yamaguchi M; Toyozawa R; Seto T; Taguchi K; Takenoyama M Ann Thorac Surg; 2020 Nov; 110(5):e377-e379. PubMed ID: 32339503 [TBL] [Abstract][Full Text] [Related]
2. Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC. Leroy T; Monnet E; Guerzider S; Jacoulet P; De Bari B; Falcoz PE; Gainet-Brun M; Lahourcade J; Alfreijat F; Almotlak H; Adotevi O; Pernet D; Polio JC; Desmarets M; Woronoff AS; Westeel V Lung Cancer; 2019 Nov; 137():23-30. PubMed ID: 31521979 [TBL] [Abstract][Full Text] [Related]
3. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749 [TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of resected metachronous second non-small cell lung cancer. Hamaji M; Ali SO; Burt BM Ann Thorac Surg; 2015 Apr; 99(4):1470-8. PubMed ID: 25725930 [TBL] [Abstract][Full Text] [Related]
5. [A case of severe colitis induced by the administration of pembrolizumab for pulmonary adenocarcinoma in a patient with ulcerative colitis]. Nishimoto N; Sakakibara Y; Ishida H; Ishihara A; Tanaka S; Hasegawa H; Yamamoto S; Nakazuru S; Mori K; Mita E Nihon Shokakibyo Gakkai Zasshi; 2021; 118(12):1122-1129. PubMed ID: 34897141 [TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676 [TBL] [Abstract][Full Text] [Related]
7. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297 [TBL] [Abstract][Full Text] [Related]
8. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report. Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943 [TBL] [Abstract][Full Text] [Related]
10. [A Case in Which Toxic Epidermal Necrosis Developed during Treatment with the Immune Checkpoint Inhibitor Pembrolizumab for Recurrent Patients Following Lung Cancer Surgery]. Tsujita T; Takahashi S; Oinuma T; Hata N Gan To Kagaku Ryoho; 2018 Nov; 45(11):1641-1644. PubMed ID: 30449854 [TBL] [Abstract][Full Text] [Related]